ES2149823T3 - Factor y composiciones que afectan al tejido dorsal. - Google Patents

Factor y composiciones que afectan al tejido dorsal.

Info

Publication number
ES2149823T3
ES2149823T3 ES93922151T ES93922151T ES2149823T3 ES 2149823 T3 ES2149823 T3 ES 2149823T3 ES 93922151 T ES93922151 T ES 93922151T ES 93922151 T ES93922151 T ES 93922151T ES 2149823 T3 ES2149823 T3 ES 2149823T3
Authority
ES
Spain
Prior art keywords
seq
noggine
noggin
dorsal
affect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922151T
Other languages
English (en)
Inventor
Richard M Harland
William C Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2149823T3 publication Critical patent/ES2149823T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE HA DESCUBIERTO UN POLIPEPTIDO NUEVO Y SOLUBLE QUE ESTA ALTAMENTE CONSERVADO EN VERTEBRADOS Y AL QUE SE DENOMINA "NOGGIN". LAS PROPIEDADES DEL NOGGIN INCLUYEN ACTIVIDAD INDUCTORA DEL CRECIMIENTO DORSAL. NOGGINA Y ACTIVINA ACTUAN SINERGICAMENTE PARA PRODUCIR MESODERMO DORSAL. EL CDNA DE NOGGINA SE HA CLONADO. DISTINTOS SISTEMAS DE EXPRESION SE HAN UTILIZADO EXITOSAMENTE PARA EXPRESAR NOGGINA BIOLOGICAMENTE ACTIVO. LAS SECUENCIAS DE AMINOACIDO QUE REPRESENTAN PORCIONES COMPLETAMENTE CONSERVADAS COMO NOGGINA DE RANA Y NOGGINA DE RATON SON: QMWLWSQTFCPVLY (SEQ ID NO: 3); RFWPRYVKVGSC (SEQ ID NO: 4); SKRSCSVPEGMVCK (SEQ ID NO: 5); LRWRCQRR (SEQ ID NO: 6) Y ISECKCSC (SEQ ID NO: 7).
ES93922151T 1992-09-03 1993-09-02 Factor y composiciones que afectan al tejido dorsal. Expired - Lifetime ES2149823T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93995492A 1992-09-03 1992-09-03

Publications (1)

Publication Number Publication Date
ES2149823T3 true ES2149823T3 (es) 2000-11-16

Family

ID=25473995

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922151T Expired - Lifetime ES2149823T3 (es) 1992-09-03 1993-09-02 Factor y composiciones que afectan al tejido dorsal.

Country Status (11)

Country Link
US (1) US5670481A (es)
EP (1) EP0662146B1 (es)
AT (1) ATE194658T1 (es)
AU (1) AU5125693A (es)
DE (1) DE69329031T2 (es)
DK (1) DK0662146T3 (es)
ES (1) ES2149823T3 (es)
GR (1) GR3034554T3 (es)
PT (1) PT662146E (es)
WO (1) WO1994005800A1 (es)
ZA (1) ZA936478B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
AU6267098A (en) * 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
WO1998037195A1 (en) * 1997-02-19 1998-08-27 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999061044A1 (en) * 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
CA2521623C (en) 2003-04-11 2015-03-17 Etex Corporation Osteoinductive bone material
SI1675608T1 (sl) 2003-09-12 2007-08-31 Wyeth Corp Injektibilne trdne paličice kalcijevega fosfata za dajanje osteogenih proteinov
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
WO2007092622A2 (en) 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
JP5484047B2 (ja) 2006-06-30 2014-05-07 バイオミメティック セラピューティクス， エルエルシー 回旋筋腱板傷害を処置するためのｐｄｇｆ−生体マトリックス組成物および方法
US20090061002A1 (en) 2007-09-05 2009-03-05 Venbrocks Rudolf A Calcium phospate based delivery of growth and differentiation factors to compromised bone
MX2011002555A (es) 2008-09-09 2011-08-03 Biomimetic Therapeutics Inc Composiciones de factor de crecimiento derivadas de plaquetas y metodo para el tratamiento de lesiones de tendon y ligamentos.
CN102811622A (zh) 2010-02-22 2012-12-05 生物模拟治疗公司 用于治疗腱病的血小板衍生生长因子组合物和方法
US10034945B2 (en) 2012-07-13 2018-07-31 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
ES2846848T3 (es) 2015-10-26 2021-07-29 Harvard College Polisacáridos reducidos y oxidados y métodos de uso de los mismos
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AT521641B1 (de) * 2018-09-12 2020-07-15 Fianostics Gmbh Verfahren zur Diagnose von Lebererkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (en) * 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
WO1986006096A1 (en) * 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IN165717B (es) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5149637A (en) * 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
WO1992005254A1 (en) * 1990-09-25 1992-04-02 Genentech, Inc. Novel neurothrophic factor

Also Published As

Publication number Publication date
US5670481A (en) 1997-09-23
WO1994005800A1 (en) 1994-03-17
PT662146E (pt) 2000-12-29
AU5125693A (en) 1994-03-29
DE69329031T2 (de) 2001-03-22
ZA936478B (en) 1994-09-30
DK0662146T3 (da) 2000-11-13
GR3034554T3 (en) 2001-01-31
DE69329031D1 (de) 2000-08-17
EP0662146A4 (en) 1996-03-13
ATE194658T1 (de) 2000-07-15
EP0662146B1 (en) 2000-07-12
EP0662146A1 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
ES2149823T3 (es) Factor y composiciones que afectan al tejido dorsal.
Sommer et al. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan
Bruckner et al. The structure of human collagen type IX and its organization in fetal and infant cartilage fibrils.
Dion et al. COOH-terminal propeptides of the major human procollagens: structural, functional and genetic comparisons
Jan et al. Fibromodulin: A regulatory molecule maintaining cellular architecture for normal cellular function
YU71395A (sh) Acilovani analozi insulina
DE69128779D1 (de) Epitheline: neue cystein-reiche, den wachstum modulierende proteine
EP0824545A4 (en) PEPTIDE COMPOUNDS WITH GROWTH FACTOR-LIKE ACTIVITY
BR9908722A (pt) Uso de derivados de ácido fumárico na medicina de transplante
CN101622007A (zh) 天然(端肽)胎盘胶原组合物
BG105764A (en) Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
KR890701607A (ko) 섬유아세포 성장 인자의 유사체
Reilly Pathogenesis of idiopathic myelofibrosis: role of growth factors.
CA2104678A1 (en) Protein-induced morphogenesis
Miller et al. Digit tip injuries: current treatment and future regenerative paradigms
Bittner et al. Modulation of collagen gel contraction by decorin
JP2012501976A (ja) ペリオスチンに誘導される膵臓再生
EP1071718A1 (en) Matrix binding factor
Gospodarowicz Molecular and developmental biology aspects of fibroblast growth factor
Strain et al. Divergent action of transforming growth factor β on DNA synthesis in human foetal liver cells
KR890006815A (ko) 산성 섬유아세포 생장인자의 돌연변이체
CN111936560A (zh) 用于刺激神经再生、骨生成和血管生成的水凝胶
Funderburgh et al. Corneal glycosaminoglycan synthesis in long-term organ culture.
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
CN1853609B (zh) 酸性纤维母细胞生长因子（fgf-1）应用于护肤功效

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 662146

Country of ref document: ES